De Bruycker Manolito, Verdonk Peter C M, Verdonk René C
Faculty of Medicine, Ghent University, De Pintelaan 185, B9000 Gent, Belgium.
Antwerp Orthopaedic Center, AZ Monica Hospitals, Harmoniestraat 68, B2018 Antwerp, Belgium - Department of Orthopaedic Surgery, Antwerp University Hospital, Wilrijkstraat, 2650 Edegem, Belgium.
SICOT J. 2017;3:33. doi: 10.1051/sicotj/2017016. Epub 2017 Apr 21.
This meta-analysis evaluates the mid- to long-term survival outcome of MAT (meniscal allograft transplantation). Potential prognosticators, with particular focus on chondral status and age of the patient at the time of transplantation, were also analysed.
Meta-analysis.
An online database search was performed using following search string: "meniscal allograft transplantation" and "outcome". A total of 65 articles were analysed for a total of 3157 performed MAT with a mean follow-up of 5.4 years. Subjective and clinical data was analysed.
The subjective and objective results of 2977 patients (3157 allografts) were analysed; 70% were male, 30% were female. Thirty-eight percent received an isolated MAT. All other patients underwent at least one concomitant procedure. Lysholm, Knee injury and Osteoarthritis Outcome (KOOS), International Knee Documentation Committee (IKDC) and Visual Analogue Scale (VAS) scores were analysed. All scores showed a good patient satisfaction at long-term follow-up. The mean overall survival rate was 80.9%. Complication rates were comparable to standard meniscal repair surgery. There was a degenerative evolution in osteoarthritis with at least one grade in 1760 radiographically analysed patients. Concomitant procedures seem to have no effect on the outcome. Age at transplantation is a negative prognosticator. The body mass index (BMI) of the patient shows a slightly negative correlation with the outcome of MAT.
MAT is a viable solution for the younger patient with chronic pain in the meniscectomised knee joint. The complications are not severe and comparable to meniscal repair. The overall failure rate at final follow-up is acceptable and the allograft heals well in most cases, but MAT cannot be seen as a definitive solution for post-meniscectomy pain. The correct approach to the chronic painful total meniscectomised knee joint thus requires consideration of all pathologies including alignment, stability, meniscal abnormality and cartilage degeneration. It requires possibly combined but appropriate action in that order.
本荟萃分析评估半月板同种异体移植(MAT)的中长期生存结果。还分析了潜在的预后因素,特别关注软骨状态和移植时患者的年龄。
荟萃分析。
使用以下搜索词进行在线数据库搜索:“半月板同种异体移植”和“结果”。共分析了65篇文章,涉及3157例MAT手术,平均随访5.4年。对主观和临床数据进行了分析。
分析了2977例患者(3157例同种异体移植)的主观和客观结果;70%为男性,30%为女性。38%接受了单纯MAT。所有其他患者至少接受了一项联合手术。分析了Lysholm评分、膝关节损伤和骨关节炎结局(KOOS)评分、国际膝关节文献委员会(IKDC)评分和视觉模拟量表(VAS)评分。所有评分在长期随访中均显示患者满意度良好。总体平均生存率为80.9%。并发症发生率与标准半月板修复手术相当。在1760例经影像学分析的患者中,骨关节炎有至少一级的退变进展。联合手术似乎对结果没有影响。移植时的年龄是一个负面预后因素。患者的体重指数(BMI)与MAT的结果呈轻微负相关。
对于半月板切除术后膝关节慢性疼痛的年轻患者,MAT是一种可行的解决方案。并发症不严重,与半月板修复相当。最终随访时的总体失败率是可以接受的,并且在大多数情况下同种异体移植愈合良好,但MAT不能被视为半月板切除术后疼痛的最终解决方案。因此,对于慢性疼痛的全半月板切除膝关节,正确的处理方法需要考虑所有病理情况,包括对线、稳定性、半月板异常和软骨退变。可能需要按此顺序采取联合但适当的行动。